# US 2018/0021359 A1 · Combination comprising an omega-3 fatty acid composition and an sglt2 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021359 A1
- Document ID: US20180021359A1
- Status: Published application
- Kind: A1
- Application number: 15/672,977
- Filed: 2017-08-09
- Published: 2018-01-25
- Earliest claimed: 2014-09-25
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Karl Erik, Goeran GANNEDAHL
- Web page: https://patentgrep.com/patent/US20180021359A1

## CPC

- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating NAFLD and/or NASH and suitable compositions for carrying out the method are claimed.

## Claims

### Claim 1

A combination of an effective dose of an omega-3 fatty acid composition wherein the omega-3 fatty acid composition contains one or more omega-3 fatty acids which may be present as acids, esters, triglycerides, phospholipids or salts and an effective dose of an SGLT-2 inhibitor or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a prodrug ester thereof, for in the treatment of non-alcoholic steatohepatitis (NASH) in a subject having, or suspected of having, NASH.

### Claim 2 (depends on 1)

A combination for use as claimed in claim 1, wherein the omega-3 composition is provided as Epanova® or a bio-equivalent version thereof.

### Claim 3 (depends on 1)

A combination for use as claimed in claim 1, wherein the SGLT-2 inhibitor is canagliflozin or ipragliflozin.

### Claim 4 (depends on 1)

A combination for use as claimed in claim 1 wherein the treatment comprises:
selecting a subject having, or suspected of having NASH on the basis of their non-alcoholic fatty liver disease (NAFLD) Activity Score;
administering an effective dose of the SGLT-2 inhibitor and an effective dose of the omega-3 fatty acid composition; and thereby improving the NAFLD Activity Score of said subject by at least 1 point, with no worsening of the subject's fibrosis stage score.

### Claim 5 (depends on 1)

A combination for use as claimed in claim 1, wherein the treatment comprises:
selecting a subject having a NAFLD Activity Score score greater than or equal to 5;
administering the combination; and thereby improving the NAFLD Activity Score of said subject by at least 1 point, with no worsening of the subject's fibrosis stage score.

### Claim 6 (depends on 1)

A combination for use as claimed in claim 1 wherein the subject has been diagnosed with Type II diabetes mellitus.

### Claim 7

A combination of an effective dose of Epanova® or a bioequivalent version thereof and an effective dose of canagliflozin or ipragliflozin, for use in the reduction of liver fat in a subject who has been diagnosed with Type II diabetes mellitus and diagnosed as having raised liver fat.

### Claim 8 (depends on 7)

A combination for use as claimed in claim 7, wherein the combination also causes a reduction in plasma triglyceride level in the subject.

### Claim 9 (depends on 7)

A combination for use as claimed in claim 7, wherein the combination also causes a raising of plasma EPA and/or DHA levels in the subject.

### Claim 10 (depends on 7)

A combination for use as claimed in claim 7, wherein the combination also causes a reduction of cell death and/or ballooning in the subject.

### Claim 11 (depends on 7)

A combination for use as claimed in claim 7, wherein the subject has a Body Mass Index (BMI)>25.

### Claim at position 12

12-16. (canceled)

### Claim 17

A combination of Epanova® or a bioequivalent version thereof and canagliflozin or ipragliflozin.

### Claim 18 (depends on 17)

A combination as claimed in claim 17 wherein 1 g, 2 g or 4 g of Epanova per day is used.

### Claim 19 (depends on 17)

A combination as claimed in claim 17, wherein 5 or 10 mg of canagliflozin or ipragliflozin is used.

### Claim 20 (depends on 17)

A combination as claimed in claim 17, wherein the combination is used in the reduction of liver fat and the reduction of liver inflammation, in a subject in need thereof.

### Claim 21 (depends on 17)

A combination as claimed in claim 17, wherein the combination is used in halting progression of liver fibrosis, in a subject in need thereof.

### Claim 22 (depends on 17)

A combination as claimed in claim 17, wherein the combination is used in halting progression of NAFLD and/or NASH comprising administering the combination and thereby causing a halt in progression of fibrosis of the subject's liver in a subject who has been diagnosed with NAFLD or NASH.

### Claim 23 (depends on 17)

A combination as claimed in claim 17, wherein the combination is used in the treatment of NASH, in a subject having, or suspected of having NASH, comprising administering the combination and thereby causing a reduction in body weight of the subject.

### Claim 24 (depends on 17)

A combination claimed in claim 17, wherein the combination is used in the treatment of NASH, in a subject having, or suspected of having NASH, comprising administering the combination and thereby causing an increase in insulin sensitisation of the subject.

### Claim 25 (depends on 17)

A combination as claimed in claim 17, wherein the combination contains an effective dose of Epanova® or a bioequivalent version thereof and an effective dose of canagliflozin or ipragliflozin.
